Previous 10 | Next 10 |
Galecto press release (NASDAQ:GLTO): FY GAAP EPS of -$2.05 beats by $0.08. Cash, cash equivalents, and investments as of December 31, 2021 were approximately $109.2 million. For further details see: Galecto GAAP EPS of -$2.05 beats by $0.08
Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development...
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating virtually at two upcoming conferences. Details for bot...
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides Update on GALACTIC-1 Trial BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biot...
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oest...
Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022 BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed company focused on the development of...
Today, we offer up our first look at a small developmental company based in Europe called Galecto. The company is targeting multiple indications and cash on the balance sheet represents all of the stock's market cap at current trading levels. A full investment analysis follows in ...
Arena Pharmaceuticals (NASDAQ:ARNA) +90% on acquisition by Pfizer. Foghorn Therapeutics (NASDAQ:FHTX) +38% after collaborating with Lilly in oncology medicines. BELLUS Health (NASDAQ:BLU) +36% on positive BLU-5937 data in mid-stage chronic cough study. Petros Pha...
GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto initiates Part 2 of Phase 1b/2a trial in patients with liver cirrhosis BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Galecto...
Galecto (NASDAQ:GLTO): Q3 GAAP EPS of -$0.50 beats by $0.06. Cash, cash equivalents, and marketable securities as of September 30, 2021 were approximately $128 million. Press Release For further details see: Galecto EPS beats by $0.06
News, Short Squeeze, Breakout and More Instantly...
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1...
Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...